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Cerebrospinal fluid phosphorylated tau proteins
as predictors of Alzheimer’s disease in subjects
with mild cognitive impairment
Abstract
Major efforts are under way to define reliable biomarkers of Alzheimer’s
disease. Highly significant increases of hyperphosphorylated tau proteins in
cerebrospinal fluid have been recently reported in Alzheimer’s disease pa-
tients compared to controls by several independent groups, including ours.
These findings support the notion that cerebrospinal fluid phosphorylated
tau proteins may be very useful biomarkers in the early identification of
Alzheimer’s disease in patients with mild cognitive impairment.
INTRODUCTION
Mild cognitive impairment (MCI) is etiologically heterogeneoussyndrome defined by cognitive impairment that can be shown by
objective neuropsychological measures adjusted for age and education.
About 40–60% of MCI patients develop Alzheimer’s disease (AD) dur-
ing the first 5 years (approximately 12–15% yearly; in contrast, only
1–2% of healthy older population convert to AD per year) (1), whereas
the rest of the MCI patients have a less progressive form of memory im-
pairment (1, 2). Other types of dementia, such as dementia with Lewy
bodies and vascular dementia, may also be preceded by MCI (2). The
amnestic subtype of MCI (i.e., memory complaint with objective me-
mory impairment, but with preservation of general cognitive function-
ing without or with minimum impairment of activities of daily living)
mostly represents prodromal AD (3). Clinically, AD cannot be diag-
nosed until dementia is present. Although the NINCDS-ADRDA cri-
teria (4) have a relatively high accuracy rate (around 80–90%) (5, 6),
these percentages come from specialized expert research academic
centres and are based on patients in later stages of the disease who were
followed longitudinally for several years before autopsy. In clinical
settings, there is no clinical method to determine which patients with
MCI will progress to dementia, except for a very long clinical follow-up.
On the other side, the introduction of new treatments and drug-mo-
difying therapies that are supposed to have best effect if introduced
early, as well as increased general knowledge on AD in the population,
have facilitated patients and their families to seek medical advice earlier
during the course of the disease. Therefore, in recent years, the preclini-
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mentia, has been the topic of increased attention. In this
article, we tried to evaluate the value of some CSF mar-
kers in predicting AD in MCI population.
SEARCH FOR AD BIOMARKERS
The pathogenic process in AD starts about 20–30
years before the clinical presentation of the disease (7, 8).
During this preclinical period there is gradual accumu-
lation of a variable amounts of amyloid plaques and
neurofibrillary tangles, and at a certain threshold the first
symptoms appear (9, 10). Although clinicopathological
correlations show best correlation of dementia with the
quantity of neurofibrillary tangles (11), the pattern of
synapse and neuron loss in AD does not necessarily
match the pattern of tangle formation (12). Because the
cerebrospinal fluid (CSF) is in direct contact with the
extracellular space of the central nervous system, it is
hoped that pathological processes characteristic of AD
are somehow reflected in CSF composition. It is also
logical to assume that candidate biomarkers for AD should
be proteins, or molecules that are intimately related with
the key pathogenic processes in the brain, i.e. the aggre-
gation of amyloid-ß with subsequent formation of plaques,
and the hyperphosphorylation of microtubule-associated
tau protein with subsequent formation of neurofibrillary
tangles. Hence, several studied CSF biomarkers (total
tau, amyloid-ß isoforms, in particular the amyloid-ß42
protein and especially several tau proteins phosphorylat-
ed on different epitopes (e.g., on threonine 181 and 231,
and on serine 199) have been found to have the highest
diagnostic potential.
AMYLOID BETA
Amyloid plaques are extracellular aggregates with 42
aa amyloid-ß peptide (amyloid-ß42) as a major compo-
nent (13). The usual finding of decreased concentration
of amyloid-ß42 in CSF of patients with AD is explained
by its accumulation in plaques. This is supported by a
strong correlation between the number of plaques found
in neocortex and hippocampus and low concentration of
amyloid-ß42 in CSF taken from intraventricular space
(14). Amyloid-ß42 has shown high sensitivity levels (78–
100%) with relatively low specificity (47–81%) in differen-
tiation of patients with AD and healthy controls (15, 16).
TAU PROTEIN
Contrary to amyloid-beta, concentrations of microtu-
bule-associated protein tau in CSF are increasing in cases
of axonal damage and therefore potentially reflect neuro-
nal degeneration and/or neuronal damage (16, 17). This
can happen not only in AD, but in a variety of acute and
subacute neurological disorders, such as acute stroke
(18) and Creutzfeldt-Jakob disease (19). When compar-
ing AD patients and healthy controls CSF total tau pro-
tein reached a sensitivity of 40–86% and a specificity of
65–86% (20). Total tau concentration in CSF roughly
correlates with the transition towards marked cognitive
impairment (16).
PHOSPHORYLATED TAU PROTEIN
In patients with AD tau protein is hyperphosphory-
lated and oxidized. Due to hyperphosphorylation tau
loses its ability to bind to the microtubules and promote
their assembly (21). More than 30 phosphorylation sites
have been described on tau in the brain (22). In contrast
to concentration of total tau protein, concentrations of
phosphorylated tau protein are not increased in CSF of
patients with acute stroke (18) and Creutzfeldt-Jakob
disease (23). With specificity of 92% in differentiating
AD patients and healthy controls, average sensitivity for
phosphorylated tau was 80% (17). In comparison with
total tau, phosphorylated tau has also showed higher
specificity in distinguishing AD from other types of de-
mentia (tau protein phosphorylated on threonine 181
showed sensitivity of 71% and specificity of 94% when
differentiating AD patients to healthy controls in compa-
rison to total tau protein which reached sensitivity of 63%
with specificity of 100% for same group differentiation)
(15).
CSF BIOMARKERS IN MCI
With the advent of new drugs such as gamma-secre-
tase inhibitors, early detection of elderly subjects with mild
cognitive impairment (MCI) who are destined to develop
AD is becoming increasingly important. The three CSF
biomarkers mentioned above (total tau, amyloid-ß42 pro-
tein and phosphorylated tau protein) have been evaluated
in numerous studies (16, 17, 20). Most of these investiga-
tions confirmed that CSF markers have high sensitivity
to differentiate early and incipient AD from normal aging,
major depressive disorder, alcoholic dementia and Par-
kinson’s disease, but lower specificity against other primary
causes of dementia syndrome, such as frontotemporal
and Lewy body dementia. Up to this moment, only a few
studies that evaluated cerebrospinal fluid biomarkers and
followed MCI patients for mainly 1–2 years have been
published. It has been shown that in group of MCI
patients, high total tau levels discriminate MCI patients
that progress to AD from those with benign form of MCI
(that do not progress to AD) with sensitivity of 90% and
specificity of 100% (24). In another study, low amy-
loid-ß42 and high total tau protein in cerebrospinal fluid
were found in 90% of the MCI cases that progressed to
AD as compared with the 10% stable MCI cases (25).
Similarly, higher concentrations of tau protein phospho-
rylated on threonine 231 were found in MCI cohort that
progressed to AD compared to those with stable MCI
(26). Additionally, Maruyama et al. (27) followed 57 MCI
patients for a period of approximately 2 years and found
higher levels of total tau protein in subjects with the
progressive form of MCI. One investigation confirmed
previous studies and showed that concentrations of amy-
loid-ß42 and total tau protein from cerebrospinal fluid
could be valuable biomarkers for early detection of AD in
MCI cohort with approximate follow-up period of 8.4
months (28). Finally, Parnetti et al. (29) have evaluated
significance of three CSF biomarkers (total tau protein,
amyloid-ß42 protein, tau protein phosphorylated on threo-
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nine 181) in prediction of conversion to AD in patients
with MCI after one year follow-up period and reported
that pathological levels in two or more CSF biomarkers
reliably predict MCI conversion to AD and correctly
identify the stable form of MCI.
SOME PROBLEMS
The major pitfall when studying CSF biomarkers to
predict AD in MCI cohorts is the fact that conversion
from MCI to AD is only about 12–15% per year. There-
fore, only an extensive follow-up time (>5 years) of pa-
tients with stable MCI might further increase the speci-
ficity of CSF biomarkers. Two studies from a group from
Finland that followed patients over period of 3 and 3.5
years, respectively, were recently published. In both of
them CSF levels of amyloid-ß42, total tau and phos-
phorylated tau proteins were measured in patients with
MCI and healthy controls (30, 31). In the first study, the
combination of amyloid-ß42 and phosphorylated tau
reached the highest level of accuracy for prediction of
MCI progression (32). Whereas in the latter combina-
tion of four parameters (amyloid-ß42, total tau and phos-
phorylated tau protein as well as apolipoprotein e4 geno-
type) was highly predictive for the dementia in MCI
patients with amnestic or executive symptoms (33). The
results of the probably most valuable study (because of
the longest follow-up period of 4–6 years, rather large
number of participants, as well as heterogeneity of possi-
ble dementia outcomes, such as progression of MCI to
vascular, diffuse Lewy body dementia, frontotemporal
dementia) suggested that by using the initial concentra-
tion of biomarkers (amyloid-ß42 protein, total tau and
tau protein phosphorylated on threonine 181), it is possi-
ble to predict accurately the progression of MCI patients
to AD (34). Interestingly, initial concentrations of above
mentioned biomarkers were useful not only to differenti-
ate progressive MCI patients (those who progressed to
AD) from stable MCI patients, but also progressive MCI
group from those who progressed to other type of demen-
tia. Yet in another study, the same authors showed the
usefulness of the Ab42/Ab40 ratio as a predictive bio-
marker for AD and confirmed that amyloid precursor
protein (APP) metabolism is disturbed early in the cour-
se of AD (33). Our group has investigated usefulness of
three CSF parameters (total tau protein, tau protein
phosphorylated on threonine 181 and serine 199) in pre-
dicting MCI progression to AD. On a rather small sam-
ple size (13 MCI patients) that we followed for a period
of at least two years (in that time 5 of them developed
AD), our results were comparable to those from other,
previously mentioned studies. CSF levels of total tau
protein and tau protein phosphorylated on threonine
181 showed excellent sensitivity and specificity when
comparing MCI patients that progressed to AD and sta-
ble MCI group (specificity when sensitivity was set at
85% or more was up to 100% for total tau protein and
80% for tau protein phosphorylated on threonine 181)
(data not shown).
OBTAINING AND STORAGE OF CSF,
PERFORMING ELISA
Lumbar puncture has to be performed to obtain CSF.
This procedure can have quite unpleasant side effects
causing postlumbar puncture headache, which is, how-
ever, in MCI patients older than 60 unusual with an inci-
dence below 2% (34, 35) and hence a largely overestimat-
ed problem. CSF should be collected in polypropylene
tubes and separated in aliquots in separate polypropy-
lene tubes to avoid repeated freeze-thaw cycles which
could lead to decrease in protein concentration. At the
end, tubes should be stored at –80oC until analysis. For
measurement of CSF biomarkers we are using commer-
cially available ELISA kits (e.g. Innotest Phospho-Tau(181p);
Innogenetics, Ghent, Belgium for measuring CSF levels
of tau protein phosphorylated on threonine 181).
CONCLUSION
From the above mentioned studies, it is evident that
CSF biomarkers are positive early in development of AD
and might be ancillary tool in differentiation and early
detection of patients prone to develop AD (which would,
in turn, accelerate proper treatment). Evidently, more
longitudinal studies are needed to clarify this issue. Ad-
ditionally, increasing numbers of investigators are trying,
by using proteomic analysis, to discover novel proteins
and peptides able to differentiate progressive MCI pa-
tients from stable MCI group. A recent study discovered
several potential biomarkers among which 5 were relevant
to the pathogenesis of AD (36). This kind of investiga-
tions could in the future help in better understanding of
the intricate molecular pathways underlying AD patho-
genesis.
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